Co-Authors
This is a "connection" page, showing publications co-authored by BOGDAN A CZERNIAK and CHRISTOPHER J LOGOTHETIS.
Connection Strength
1.303
-
Erratum: The origin of bladder cancer from mucosal field effects. iScience. 2022 Jul 15; 25(7):104715.
Score: 0.221
-
The origin of bladder cancer from mucosal field effects. iScience. 2022 Jul 15; 25(7):104551.
Score: 0.220
-
Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Sci Rep. 2020 06 16; 10(1):9743.
Score: 0.192
-
Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. iScience. 2020 Jun 26; 23(6):101201.
Score: 0.191
-
Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Rep. 2019 02 19; 26(8):2241-2256.e4.
Score: 0.175
-
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. 2023 12; 6(6):611-620.
Score: 0.060
-
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun. 2022 04 04; 13(1):1797.
Score: 0.054
-
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol. 2023 04; 6(2):228-232.
Score: 0.053
-
Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene. 1999 Feb 04; 18(5):1185-96.
Score: 0.044
-
Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia. Oncogene. 1997 May 01; 14(17):2059-70.
Score: 0.039
-
Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):107-21.
Score: 0.034
-
Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis. Cancer Biol Ther. 2008 Oct; 7(10):1619-27.
Score: 0.021